Processing

Please wait...

Settings

Settings

1. WO2000039155 - PENICILLINS AS PHARMACEUTICALS FOR THE DOWNREGULATION OF IFN$g(g) PRODUCTION

Publication Number WO/2000/039155
Publication Date 06.07.2000
International Application No. PCT/EP1999/010378
International Filing Date 23.12.1999
Chapter 2 Demand Filed 06.06.2000
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 7/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
02Linear peptides containing at least one abnormal peptide link
C07K 14/33 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
G01N 33/94 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94involving narcotics
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/645
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
A61K 47/646
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
646the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
C07K 14/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
C07K 7/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
02Linear peptides containing at least one abnormal peptide link
G01N 33/9446
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94involving narcotics ; or drugs or pharmaceuticals, neurotransmitters or associated receptors
9446Antibacterials
Applicants
  • MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstrasse 8 D-80539 München, DE (AllExceptUS)
  • PADOVAN, Elisabetta [IT/CH]; CH (UsOnly)
  • WELTZIEN, Hans, Ulrich [DE/DE]; DE (UsOnly)
Inventors
  • PADOVAN, Elisabetta; CH
  • WELTZIEN, Hans, Ulrich; DE
Agents
  • WEICKMANN, H. ; Kopernikusstrasse 9 D-81679 München, DE
Priority Data
98124591.323.12.1998EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PENICILLINS AS PHARMACEUTICALS FOR THE DOWNREGULATION OF IFN$g(g) PRODUCTION
(FR) PENICILLINES UTILISEES COMME AGENT PHARMACEUTIQUE DANS LA REGULATION NEGATIVE DE LA PRODUCTION D'IFN$g(g)
Abstract
(EN)
According to the present invention, penicillins are used for the production of a pharmaceutical for therapeutic use in autoimmune diseases or other pathological situations where IFN$g(g)-mediated effects are involved in the progression of the disease. Another use of the invention relates to hapten-modified peptides for the production of a pharmaceutical for therapeutic use in autoimmune diseases or other pathological situations where IFN$g(g) mediated effects are involved in the progression of the disease.
(FR)
Selon la présente invention, des pénicillines sont utilisées dans la production d'un agent pharmaceutique destiné à une utilisation thérapeutique dans des maladies auto-immunes ou autres situations pathologiques dans lesquelles des effets induits par IFN$g(g) sont impliqués dans la progression de la maladie. Une autre utilisation de l'invention concerne des peptides modifiés par haptènes dans la production d'un agent pharmaceutique destiné à une utilisation pharmaceutique dans des maladies auto-immunes ou autres situations pathologiques dans lesquelles les effets induits par l'IFN$g(g) sont impliqués dans la progression de la maladie.
Also published as
US09869027
Latest bibliographic data on file with the International Bureau